{
    "q": [
        {
            "docid": "18398577_15",
            "document": "Somatic evolution in cancer . System instability is a major contributing factor for genetic heterogeneity. For the majority of cancers, genome instability is reflected in a large frequency of mutations in the whole genome DNA sequence (not just the protein coding regions that are only 1.5% of the genome). In whole genome sequencing of different types of cancers, large numbers of mutations were found in two breast cancers (about 20,000 point mutations), 25 melanomas (9,000 to 333,000 point mutations) and a lung cancer (50,000 point mutations and 54,000 small additions and deletions). Genome instability is also referred to as an enabling characteristic for achieving endpoints of cancer evolution. Many of the somatic evolutionary studies have traditionally been focused on clonal expansion, as recurrent types of changes can be traced to illustrate the evolutionary path based on available methods. Recent studies from both direct DNA sequencing and karyotype analysis illustrate the importance of the high level of heterogeneity in somatic evolution. For the formation of solid tumors, there is an involvement of multiple cycles of clonal and non-clonal expansion. Even at the typical clonal expansion phase, there are significant levels of heterogeneity within the cell population, however, most are under-detected when mixed populations of cells are used for molecular analysis. In solid tumors, a majority of gene mutations are not recurrent types, and neither are the karyotypes. These analyses offer an explanation for the findings that there are no common mutations shared by most cancers.",
            "score": 217.97339928150177
        },
        {
            "docid": "53264736_4",
            "document": "Nuria Lopez Bigas . L\u00f3pez-Bigas' lab has contributed to the identification of genes that drive abnormal growth of malignant cells, known as cancer driver genes. During tumorigenesis, positive selection of mutations that activate the tumorigenic potential of oncogenes occur. Her lab has developed computational methodologies to detect these signals of positive selection in the pattern of somatic mutations observed in tumors. They developed pioneer methods to identify cancer driver genes through the creation of IntOGen. This web platform supports cancer researchers by providing a systematic analysis of oncogene data across various sequencing projects to aid in clinical decision-making. The lab is also involved in advancing precision medicine by using targetable gene alterations to help determine therapeutic options for cancer patients. They have developed an approach that uses bioinformatic resources to identify therapeutically actionable genomic alterations in tumors, which is accessible through another online database called the Cancer Genome Interpreter.",
            "score": 171.7472048997879
        },
        {
            "docid": "1236730_32",
            "document": "Neoplasm . Cancers are known to exhibit genome instability or a mutator phenotype. The protein-coding DNA within the nucleus is about 1.5% of the total genomic DNA. Within this protein-coding DNA (called the exome), an average cancer of the breast or colon can have about 60 to 70 protein altering mutations, of which about 3 or 4 may be \u201cdriver\u201d mutations, and the remaining ones may be \u201cpassenger\u201d mutations However, the average number of DNA sequence mutations in the entire genome (including non-protein-coding regions) within a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000. This compares to the very low mutation frequency of about 70 new mutations in the entire genome between generations (parent to child) in humans.",
            "score": 261.1522397994995
        },
        {
            "docid": "2332422_24",
            "document": "Carcinogenesis . Cancers are known to exhibit genome instability or a mutator phenotype. The protein-coding DNA within the nucleus is about 1.5% of the total genomic DNA. Within this protein-coding DNA (called the exome), an average cancer of the breast or colon can have about 60 to 70 protein altering mutations, of which about 3 or 4 may be \"driver\" mutations, and the remaining ones may be \"passenger\" mutations. However, the average number of DNA sequence mutations in the entire genome (including non-protein-coding regions) within a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000. These high frequencies of mutations in the total nucleotide sequences within cancers suggest that often an early alteration in the field defect giving rise to a cancer (e.g. yellow area in the diagram in the preceding section) is a deficiency in DNA repair. Large field defects surrounding colon cancers (extending to about 10\u00a0cm on each side of a cancer) are found to frequently have epigenetic defects in 2 or 3 DNA repair proteins (ERCC1, XPF and/or PMS2) in the entire area of the field defect. When expression of DNA repair genes is reduced, DNA damages accumulate in cells at a higher than normal level, and these excess damages cause increased frequencies of mutation and/or epimutation. Mutation rates strongly increase in cells defective in DNA mismatch repair or in homologous recombinational repair (HRR). A deficiency in DNA repair, itself, can allow DNA damages to accumulate, and error-prone translesion synthesis past some of those damages may give rise to mutations. In addition, faulty repair of these accumulated DNA damages may give rise to epimutations. These new mutations and/or epimutations may provide a proliferative advantage, generating a field defect. Although the mutations/epimutations in DNA repair genes do not, themselves, confer a selective advantage, they may be carried along as passengers in cells when the cell acquires an additional mutation/epimutation that does provide a proliferative advantage.",
            "score": 252.35370910167694
        },
        {
            "docid": "8842207_10",
            "document": "Cancer Genome Project . The leader of the Nik-Zainal group is Dr.Serena Nik-Zainal. The group uses computational methods to identify the unique signature of mutagenesis in somatic cells to help increase the understanding of how mutations in DNA contribute to aging and cancer. As more cancer genomes are sequenced the information the group generates will encompass a more robust collection, allowing for understanding of how mutations lead to different types and even subtypes of cancer.",
            "score": 173.29540967941284
        },
        {
            "docid": "4087965_15",
            "document": "Genetic analysis . This research has been able to identify the concepts of genetic mutations, fusion genes and changes in DNA copy numbers, and advances are made in the field every day. Much of these applications have led to new types of sciences that use the foundations of genetic analysis. Reverse genetics uses the methods to determine what is missing in a genetic code or what can be added to change that code. Genetic linkage studies analyze the spatial arrangements of genes and chromosomes. There have also been studies to determine the legal and social and moral effects of the increase of genetic analysis. Genetic analysis may be done to identify genetic/inherited disorders and also to make a differential diagnosis in certain somatic diseases such as cancer. Genetic analyses of cancer include detection of mutations, fusion genes, and DNA copy number changes.",
            "score": 206.762868642807
        },
        {
            "docid": "70425_38",
            "document": "Inflammation . Genome-wide analyses of human cancer tissues reveal that a single typical cancer cell may possess roughly 100 mutations in coding regions, 10-20 of which are \u201cdriver mutations\u201d that contribute to cancer development. However, chronic inflammation also causes epigenetic changes such as DNA methylations, that are often more common than mutations. Typically, several hundreds to thousands of genes are methylated in a cancer cell (see DNA methylation in cancer). Sites of oxidative damage in chromatin can recruit complexes that contain DNA methyltransferases (DNMTs), a histone deacetylase (SIRT1), and a histone methyltransferase (EZH2), and thus induce DNA methylation. DNA methylation of a CpG island in a promoter region may cause silencing of its downstream gene (see CpG site and regulation of transcription in cancer). DNA repair genes, in particular, are frequently inactivated by methylation in various cancers (see hypermethylation of DNA repair genes in cancer). A 2018 report evaluated the relative importance of mutations and epigenetic alterations in progression to two different types of cancer. This report showed that epigenetic alterations were much more important than mutations in generating gastric cancers (associated with inflammation). However, mutations and epigenetic alterations were of roughly equal importance in generating esophageal squamous cell cancers (associated with tobacco chemicals and acetaldehyde, a product of alcohol metabolism).",
            "score": 215.26904821395874
        },
        {
            "docid": "21003747_10",
            "document": "High Resolution Melt . In a field more relevant to clinical diagnostics, HRM has been shown to be suitable in principle for the detection of mutations in the breast cancer susceptibility genes BRCA1 and BRCA2. More than 400 mutations have been identified in these genes.The sequencing of genes is the gold standard for identifying mutations. Sequencing is time consuming and labour-intensive and is often preceded by techniques used to identify heteroduplex DNA, which then further amplify these issues. HRM offers a faster and more convenient closed-tube method of assessing the presence of mutations and gives a result which can be further investigated if it is of interest. In a study carried out by Scott et al. in 2006, 3 cell lines harbouring different BRCA mutations were used to assess the HRM methodology. It was found that the melting profiles of the resulting PCR products could be used to distinguish the presence or absence of a mutation in the amplicon. Similarly in 2007 Krypuy et al. showed that the careful design of HRM assays (with regards to primer placement) could be successfully employed to detect mutations in the TP53 gene, which encodes the tumour suppressor protein p53 in clinical samples of breast and ovarian cancer. Both these studies highlighted the fact that changes in the melting profile can be in the form of a shift in the melting temperature or an obvious difference in the shape of the melt curve. Both of these parameters are a function of the amplicon sequence. The consensus is that HRM is a cost efficient method that can be employed as an initial screen for samples suspected of harbouring polymorphisms or mutations. This would reduce the number of samples which need to be investigated further using more conventional methods.",
            "score": 174.49594831466675
        },
        {
            "docid": "35746225_2",
            "document": "Cancer epigenetics . Cancer epigenetics is the study of epigenetic modifications to the DNA of cancer cells that do not involve a change in the nucleotide sequence. Epigenetic alterations may be just as important, or even more important, than genetic mutations in a cell's transformation to cancer. In cancers, loss of expression of genes occurs about 10 times more frequently by transcription silencing (caused by epigenetic promoter hypermethylation of CpG islands) than by mutations. As Vogelstein et al. point out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. However, in colon tumors compared to adjacent normal-appearing colonic mucosa, there are about 600 to 800 heavily methylated CpG islands in promoters of genes in the tumors while these CpG islands are not methylated in the adjacent mucosa. Manipulation of epigenetic alterations holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. Several medications which have epigenetic impact are now used in several of these diseases.",
            "score": 200.82121443748474
        },
        {
            "docid": "21647820_36",
            "document": "Whole genome sequencing . In cancer, mutation frequencies are much higher, due to genome instability. This frequency can further depend on patient age, exposure to DNA damaging agents (such as UV-irradiation or components of tobacco smoke) and the activity/inactivity of DNA repair mechanisms. Furthermore, mutation frequency can vary between cancer types: in germline cells, mutation rates occur at approximately 0.023 mutations per megabase, but this number is much higher in breast cancer (1.18-1.66 somatic mutations per Mb), in lung cancer (17.7) or in melanomas (~33). Since the haploid human genome consists of approximately 3,200 megabases, this translates into about 74 mutations (mostly in noncoding regions) in germline DNA per generation, but 3,776-5,312 somatic mutations per haploid genome in breast cancer, 56,640 in lung cancer and 105,600 in melanomas.",
            "score": 172.19953417778015
        },
        {
            "docid": "26062564_26",
            "document": "Cancer genome sequencing . A major goal of cancer genome sequencing is to identify driver mutations: genetic changes which increase the mutation rate in the cell, leading to more rapid tumor evolution and metastasis. It is difficult to determine driver mutations from DNA sequence alone; but drivers tend to be the most commonly shared mutations amongst tumors, cluster around known oncogenes, and are tend to be non-silent. Passenger mutations, which are not important in the progression of the disease, are randomly distributed throughout the genome. It has been estimated that the average tumor carries c.a. 80 somatic mutations, fewer than 15 of which are expected to be drivers.",
            "score": 212.51981449127197
        },
        {
            "docid": "18844072_11",
            "document": "Synthetic lethality . About 3 or 4 driver mutations and 60 passenger mutations occur in the exome (protein coding region) of a cancer. However, a much larger number of mutations occur in the non-protein-coding regions of DNA in a cancer. The average number of DNA sequence mutations in the entire genome of a breast cancer tissue sample is much higher, about 20,000. In an average melanoma tissue sample the total number of DNA sequence mutations is about 80,000.",
            "score": 241.09114789962769
        },
        {
            "docid": "32706791_16",
            "document": "Genome instability . As noted above, about 3 or 4 driver mutations and 60 passenger mutations occur in the exome (protein coding region) of a cancer. However, a much larger number of mutations occur in the non-protein-coding regions of DNA. The average number of DNA sequence mutations in the entire genome of a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000.",
            "score": 241.68842840194702
        },
        {
            "docid": "610997_20",
            "document": "Frameshift mutation . Frameshift mutations are known to be a factor in colorectal cancer as well as other cancers with microsatellite instability. As stated previously, frameshift mutations are more likely to occur in a region of repeat sequence. When DNA mismatch repair does not fix the addition or deletion of bases, these mutations are more likely to be pathogenic. This may be in part because the tumor is not told to stop growing. Experiments in yeast and bacteria help to show characteristics of microsatellites that may contribute to defective DNA mismatch repair. These include the length of the microsatellite, the makeup of the genetic material and how pure the repeats are. Based on experimental results longer microsatellites have a higher rate of frameshift mutations. The flanking DNA can also contribute to frameshift mutations. In prostate cancer a frameshift mutation changes the open reading frame (ORF) and prevents apoptosis from occurring. This leads to an unregulated growth of the tumor. While there are environmental factors that contribute to the progression of prostate cancer, there is also a genetic component. During testing of coding regions to identify mutations, 116 genetic variants were discovered, including 61 frameshift mutations. There are over 500 mutations on chromosome 17 that seem to play a role in the development of breast and ovarian cancer in the BRCA1 gene, many of which are frameshift.",
            "score": 184.11009192466736
        },
        {
            "docid": "27849090_6",
            "document": "Michael Stratton . At the announcement of the completion of the Human Genome Project in 2000, Stratton discussed using genome sequences to revolutionise cancer treatment. He and Andy Futreal had already initiated the Cancer Genome Project at the Sanger Centre, as it was then known, to use genome-wide analysis to find somatic mutations in human cancers. According to fellow cancer researcher Chris Marshall, doing so prior to the completion of the human genome sequence was an \"audacious idea.\" The aims of the project are to identify new cancer genes, to understand how cancers develop and to study how the structure of genomes influence cancer. In 2002 and 2004, Stratton's team discovered mutations in the BRAF and ERBB2 genes in approximately 60 per cent of malignant melanomas and 4 per cent of non-small-cell lung cancers respectively.",
            "score": 151.5107536315918
        },
        {
            "docid": "28646010_7",
            "document": "COSMIC cancer database . The COSMIC database contains thousands of somatic mutations that are implicated in the development of cancer. The database collects information from two major sources. Firstly, mutations in known cancer genes are collected from the literature. The list of genes that undergo manual curation are identified by their presence in the Cancer Gene Census. Secondly, data for inclusion in the database is collected from whole genome resequencing studies of cancer samples undertaken by the Cancer Genome Project. For example, Campbell and colleagues used next generation sequencing to examine samples from two individuals with lung cancer which led to the identification of 103 somatic DNA rearrangements.",
            "score": 163.8336067199707
        },
        {
            "docid": "5037034_13",
            "document": "P300-CBP coactivator family . Mutations in the p300 gene have been identified in several other types of cancer. These mutations are somatic, which means they are acquired during a person's lifetime and are present only in certain cells. Somatic mutations in the p300 gene have been found in a small number of solid tumors, including cancers of the colon and rectum, stomach, breast and pancreas. Studies suggest that p300 mutations may also play a role in the development of some prostate cancers, and could help predict whether these tumors will increase in size or spread to other parts of the body. In cancer cells, p300 mutations prevent the gene from producing any functional protein. Without p300, cells cannot effectively restrain growth and division, which can allow cancerous tumors to form.",
            "score": 143.24066197872162
        },
        {
            "docid": "3429588_11",
            "document": "EP300 . Mutations in the EP300 gene have been identified in several other types of cancer. These mutations are somatic, which means they are acquired during a person's lifetime and are present only in certain cells. Somatic mutations in the EP300 gene have been found in a small number of solid tumors, including cancers of the colon and rectum, stomach, breast, and pancreas. Studies suggest that EP300 mutations may also play a role in the development of some prostate cancers, and could help predict whether these tumors will increase in size or spread to other parts of the body. In cancer cells, EP300 mutations prevent the gene from producing any functional protein. Without p300, cells cannot effectively restrain growth and division, which can allow cancerous tumors to form.",
            "score": 143.24066197872162
        },
        {
            "docid": "4214_26",
            "document": "Bioinformatics . In cancer, the genomes of affected cells are rearranged in complex or even unpredictable ways. Massive sequencing efforts are used to identify previously unknown point mutations in a variety of genes in cancer. Bioinformaticians continue to produce specialized automated systems to manage the sheer volume of sequence data produced, and they create new algorithms and software to compare the sequencing results to the growing collection of human genome sequences and germline polymorphisms. New physical detection technologies are employed, such as oligonucleotide microarrays to identify chromosomal gains and losses (called comparative genomic hybridization), and single-nucleotide polymorphism arrays to detect known \"point mutations\". These detection methods simultaneously measure several hundred thousand sites throughout the genome, and when used in high-throughput to measure thousands of samples, generate terabytes of data per experiment. Again the massive amounts and new types of data generate new opportunities for bioinformaticians. The data is often found to contain considerable variability, or noise, and thus Hidden Markov model and change-point analysis methods are being developed to infer real copy number changes.",
            "score": 160.9298210144043
        },
        {
            "docid": "7737653_23",
            "document": "Oncogenomics . Another (agnostic) way to analyze the observed mutational spectra and DNA sequence context of mutations in tumors involves pooling all mutations of different types and contexts from cancer samples into a discrete distribution. If multiple cancer samples are available, their context-dependent mutations can be represented in the form of a nonnegative matrix. This matrix can be further decomposed into components (mutational signatures) which ideally should describe individual mutagenic factors. Several computational methods have been proposed for solving this decomposition problem. The first implementation of Non-negative Matrix Factorization (NMF) method is available in Sanger Institute Mutational Signature Framework in the form of a MATLAB package. On the other hand, if mutations from a single tumor sample are only available, the DeconstructSigs R package and MutaGene server may provide the identification of contributions of different mutational signatures for a single tumor sample. In addition, MutaGene server provides mutagen or cancer-specific mutational background models and signatures that can be applied to calculate expected DNA and protein site mutability to decouple relative contributions of mutagenesis and selection in carcinogenesis.",
            "score": 151.7322142124176
        },
        {
            "docid": "413102_15",
            "document": "Folding@home . More than half of all known cancers involve mutations of p53, a tumor suppressor protein present in every cell which regulates the cell cycle and signals for cell death in the event of damage to DNA. Specific mutations in p53 can disrupt these functions, allowing an abnormal cell to continue growing unchecked, resulting in the development of tumors. Analysis of these mutations helps explain the root causes of p53-related cancers. In 2004, Folding@home was used to perform the first molecular dynamics study of the refolding of p53's protein dimer in an all-atom simulation of water. The simulation's results agreed with experimental observations and gave insights into the refolding of the dimer that were formerly unobtainable. This was the first peer reviewed publication on cancer from a distributed computing project. The following year, Folding@home powered a new method to identify the amino acids crucial for the stability of a given protein, which was then used to study mutations of p53. The method was reasonably successful in identifying cancer-promoting mutations and determined the effects of specific mutations which could not otherwise be measured experimentally.",
            "score": 158.945605635643
        },
        {
            "docid": "14082598_37",
            "document": "BRAF (gene) . More than 30 mutations of the \"BRAF\" gene associated with human cancers have been identified. The frequency of BRAF mutations varies widely in human cancers, from more than 80% in melanomas and nevi, to as little as 0\u201318% in other tumors, such as 1\u20133% in lung cancers and 5% in colorectal cancer. In 90% of the cases, thymine is substituted with adenine at nucleotide 1799. This leads to valine (V) being substituted for by glutamate (E) at codon 600 (now referred to as V600E) in the activation segment that has been found in human cancers. This mutation has been widely observed in papillary thyroid carcinoma, colorectal cancer, melanoma and non-small-cell lung cancer. BRAF-V600E mutation are present in 57% of Langerhans cell histiocytosis patients. The V600E mutation is a likely driver mutation in 100% of cases of hairy cell leukaemia. High frequency of BRAF V600E mutations have been detected in ameloblastoma, a benign but locally infiltrative odontogenic neoplasm. The V600E mutation may also be linked, as a single-driver mutation (a genetic 'smoking gun') to certain cases of papillary craniopharyngioma development.",
            "score": 144.62584245204926
        },
        {
            "docid": "35746225_32",
            "document": "Cancer epigenetics . Cancers have high levels of genome instability, associated with a high frequency of mutations. A high frequency of genomic mutations increases the likelihood of particular mutations occurring that activate oncogenes and inactivate tumor suppressor genes, leading to carcinogenesis. On the basis of whole genome sequencing, cancers are found to have thousands to hundreds of thousands of mutations in their whole genomes. (Also see Mutation frequencies in cancers.) By comparison, the mutation frequency in the whole genome between generations for humans (parent to child) is about 70 new mutations per generation. In the protein coding regions of the genome, there are only about 0.35 mutations between parent/child generations (less than one mutated protein per generation). Whole genome sequencing in blood cells for a pair of identical twin 100-year-old centenarians only found 8 somatic differences, though somatic variation occurring in less than 20% of blood cells would be undetected.",
            "score": 163.6145964860916
        },
        {
            "docid": "68300_43",
            "document": "Dominance (genetics) . A dominant-negative mutation may arise in a human somatic cell and provide a proliferative advantage to the mutant cell, leading to its clonal expansion. For instance, a dominant-negative mutation in a gene necessary for the normal process of programmed cell death (Apoptosis) in response to DNA damage can make the cell resistant to apoptosis. This will allow proliferation of the clone even when excessive DNA damage is present. Such dominant-negative mutations occur in the tumor suppressor gene \"p53\". The P53 wild-type protein is normally present as a four-protein multimer (oligotetramer). Dominant-negative \"p53\" mutations occur in a number of different types of cancer and pre-cancerous lesions (e.g. brain tumors, breast cancer, oral pre-cancerous lesions and oral cancer).",
            "score": 166.05542087554932
        },
        {
            "docid": "8842207_13",
            "document": "Cancer Genome Project . In an attempt to better understand the mechanics of the mutations that lead to the development of cancer the Nik-Zainal group carried out a study that involved the cataloging of the somatic mutations for 21 different breast cancers. The group then utilized mathematical methods to help determine the unique mutational signatures of the underlying processes leading to the evolution from healthy to diseased tissue for each of the sampled cancers. The results showed that the mutations included several single and double nucleotide substitutions that were able to be differentiated. The unique mutations for each cancer allowed for the 21 samples to be categorized based off type and subtype of cancer, showing a relationship between mutations and the type of resulting cancer. While the group was able to identify these mutations they were unable to determine the underlying mechanisms resulting in them.",
            "score": 117.27996921539307
        },
        {
            "docid": "8842207_3",
            "document": "Cancer Genome Project . The project operates within the scope of the International Cancer Genome Consortium, working with the other participating organizations and countries to build a database of genomic changes present in different types of cancer. The somatic mutation information gathered by the project can be located in the COSMIC database. The Wellcome Trust Sanger Institute's project currently has several internal partners that each focus on different types of cancer and mutagenesis utilizing different methods. Research goes beyond just sequencing to include therapeutic biomarker discoveries made utilizing bioinformatics programs. Among these discoveries are drug sensitivity biomarkers and inhibitor biomarkers. These discoveries paired with the evolution of DNA sequencing technologies to next-generation sequencing techniques, are important in potential disease treatment and may even help lead to more personalized medicine for cancer patients.",
            "score": 176.1305911540985
        },
        {
            "docid": "45031863_7",
            "document": "Liquid biopsy . Liquid biopsies have been made possible by advances in sequencing the human genome, since scientists and researchers can now detect genetic mutations of cancers. Researchers have found that unique cancer mutations can show up in microscopic fragments of DNA in a patient's blood. Tumor-related circulating-free DNA, RNA or proteins are released by tumor cells and circulate in the blood of cancer patients. Therefore, assays using these molecules can be used for early tumor detection, monitoring or detection of resistance mutations.",
            "score": 184.99729204177856
        },
        {
            "docid": "7140680_9",
            "document": "Biomarker (cell) . Genomic biomarkers analyze DNA by identifying irregular sequences in the genome, typically a single nucleotide polymorphism. Genetic biomarkers are particularly significant in cancer because most cancer cell lines carry somatic mutations. Somatic mutations are distinguishable from hereditary mutations because the mutation is not in every cell; just the tumor cells, making them easy targets.",
            "score": 158.8977028131485
        },
        {
            "docid": "14088001_27",
            "document": "War on Cancer . High-throughput DNA sequencing has been used to study the whole genome sequence of two different cancer tissues: a small-cell lung cancer metastasis and a malignant melanoma cell line. The sequence information provides a comprehensive catalog of approximately 90% of the somatic mutations in the cancerous tissue, providing a more detailed molecular and genetic understanding of cancer biology than was previously possible, and offering hope for the development of new therapeutic strategies gleaned from these insights.",
            "score": 157.35597467422485
        },
        {
            "docid": "1264722_10",
            "document": "Malignant transformation . One underlying commonality in cancers is genetic mutation, acquired either by inheritance, or, more commonly, by mutations in one's somatic DNA over time. The mutations considered important in cancers are those that alter protein coding genes (the exome). As Vogelstein et al. point out, a typical tumor contains two to eight exome \"driver gene\" mutations, and a larger number of exome mutations that are \"passengers\" that confer no selective growth advantage.",
            "score": 187.7861831188202
        },
        {
            "docid": "36777018_4",
            "document": "Causes of cancer . Many of these syndromes are caused by mutations in tumor suppressor genes that regulate cell growth. Other common mutations alter the function of DNA repair genes, oncogenes and genes involved in the production of blood vessels. Certain inherited mutations in the genes \"BRCA1\" and \"BRCA2\" with a more than 75% risk of breast cancer and ovarian cancer. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of colon cancer cases. In many cases, genetic testing can be used to identify mutated genes or chromosomes that are passed through generations.",
            "score": 143.08241152763367
        },
        {
            "docid": "541499_32",
            "document": "Indoor tanning . Exposure to ultraviolet radiation (UVR), whether from the sun or tanning devices is known to be a major cause of the three main types of skin cancer: non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) and melanoma. Overexposure to UVR induces at least two types of DNA damage: cyclobutane\u2013pyrimidine dimers (CPDs) and 6\u20134 photoproducts (6\u20134PPs). While DNA repair enzymes can fix some mutations, if they are not sufficiently effective, a cell will acquire genetic mutations which may cause the cell to die or become cancerous. These mutations can result in cancer, aging, persistent mutation and cell death. For example, squamous cell carcinoma can be caused by a UVB-induced mutation in the p53 gene.",
            "score": 135.82620918750763
        }
    ],
    "r": [
        {
            "docid": "1236730_32",
            "document": "Neoplasm . Cancers are known to exhibit genome instability or a mutator phenotype. The protein-coding DNA within the nucleus is about 1.5% of the total genomic DNA. Within this protein-coding DNA (called the exome), an average cancer of the breast or colon can have about 60 to 70 protein altering mutations, of which about 3 or 4 may be \u201cdriver\u201d mutations, and the remaining ones may be \u201cpassenger\u201d mutations However, the average number of DNA sequence mutations in the entire genome (including non-protein-coding regions) within a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000. This compares to the very low mutation frequency of about 70 new mutations in the entire genome between generations (parent to child) in humans.",
            "score": 261.1522216796875
        },
        {
            "docid": "2332422_24",
            "document": "Carcinogenesis . Cancers are known to exhibit genome instability or a mutator phenotype. The protein-coding DNA within the nucleus is about 1.5% of the total genomic DNA. Within this protein-coding DNA (called the exome), an average cancer of the breast or colon can have about 60 to 70 protein altering mutations, of which about 3 or 4 may be \"driver\" mutations, and the remaining ones may be \"passenger\" mutations. However, the average number of DNA sequence mutations in the entire genome (including non-protein-coding regions) within a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000. These high frequencies of mutations in the total nucleotide sequences within cancers suggest that often an early alteration in the field defect giving rise to a cancer (e.g. yellow area in the diagram in the preceding section) is a deficiency in DNA repair. Large field defects surrounding colon cancers (extending to about 10\u00a0cm on each side of a cancer) are found to frequently have epigenetic defects in 2 or 3 DNA repair proteins (ERCC1, XPF and/or PMS2) in the entire area of the field defect. When expression of DNA repair genes is reduced, DNA damages accumulate in cells at a higher than normal level, and these excess damages cause increased frequencies of mutation and/or epimutation. Mutation rates strongly increase in cells defective in DNA mismatch repair or in homologous recombinational repair (HRR). A deficiency in DNA repair, itself, can allow DNA damages to accumulate, and error-prone translesion synthesis past some of those damages may give rise to mutations. In addition, faulty repair of these accumulated DNA damages may give rise to epimutations. These new mutations and/or epimutations may provide a proliferative advantage, generating a field defect. Although the mutations/epimutations in DNA repair genes do not, themselves, confer a selective advantage, they may be carried along as passengers in cells when the cell acquires an additional mutation/epimutation that does provide a proliferative advantage.",
            "score": 252.3537139892578
        },
        {
            "docid": "32706791_16",
            "document": "Genome instability . As noted above, about 3 or 4 driver mutations and 60 passenger mutations occur in the exome (protein coding region) of a cancer. However, a much larger number of mutations occur in the non-protein-coding regions of DNA. The average number of DNA sequence mutations in the entire genome of a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000.",
            "score": 241.6884307861328
        },
        {
            "docid": "18844072_11",
            "document": "Synthetic lethality . About 3 or 4 driver mutations and 60 passenger mutations occur in the exome (protein coding region) of a cancer. However, a much larger number of mutations occur in the non-protein-coding regions of DNA in a cancer. The average number of DNA sequence mutations in the entire genome of a breast cancer tissue sample is much higher, about 20,000. In an average melanoma tissue sample the total number of DNA sequence mutations is about 80,000.",
            "score": 241.0911407470703
        },
        {
            "docid": "44284_29",
            "document": "Non-coding DNA . Many noncoding DNA sequences must have some important biological function. This is indicated by comparative genomics studies that report highly conserved regions of noncoding DNA, sometimes on time-scales of hundreds of millions of years. This implies that these noncoding regions are under strong evolutionary pressure and positive selection. For example, in the genomes of humans and mice, which diverged from a common ancestor 65\u201375 million years ago, protein-coding DNA sequences account for only about 20% of conserved DNA, with the remaining 80% of conserved DNA represented in noncoding regions. Linkage mapping often identifies chromosomal regions associated with a disease with no evidence of functional coding variants of genes within the region, suggesting that disease-causing genetic variants lie in the noncoding DNA. The significance of noncoding DNA mutations in cancer was explored in April 2013.",
            "score": 233.90830993652344
        },
        {
            "docid": "2140955_5",
            "document": "ENCODE . Humans are estimated to have approximately 20,000 protein-coding genes, which account for about 1.5% of DNA in the human genome. The primary goal of the ENCODE project is to determine the role of the remaining component of the genome, much of which was traditionally regarded as \"junk.\" The activity and expression of protein-coding genes can be modulated by the regulome - a variety of DNA elements, such as the promoter, transcriptional regulatory sequences, and regions of chromatin structure and histone modification. It is thought that changes in the regulation of gene activity can disrupt protein production and cell processes and result in disease. Determining the location of these regulatory elements and how they influence gene transcription could reveal links between variations in the expression of certain genes and the development of disease.",
            "score": 230.843994140625
        },
        {
            "docid": "31001114_15",
            "document": "DNA nanoball sequencing . DNA nanoball sequencing has been used in recent studies. Lee \"et al.\" used this technology to find mutations that were present in a lung cancer and compared them to normal lung tissue. They were able to identify over 50,000 single nucleotide variants. Roach \"et al.\" used DNA nanoball sequencing to sequence the genomes of a family of four relatives and were able to identify SNPs that may be responsible for a Mendelian disorder, and were able to estimate the inter-generation mutation rate. The Institute for Systems Biology has used this technology to sequence 615 complete human genome samples as part of a survey studying neurodegenerative diseases, and the National Cancer Institute is using DNA nanoball sequencing to sequence 50 tumours and matched normal tissues from pediatric cancers.",
            "score": 229.5985565185547
        },
        {
            "docid": "7955_74",
            "document": "DNA . Bioinformatics involves the development of techniques to store, data mine, search and manipulate biological data, including DNA nucleic acid sequence data. These have led to widely applied advances in computer science, especially string searching algorithms, machine learning, and database theory. String searching or matching algorithms, which find an occurrence of a sequence of letters inside a larger sequence of letters, were developed to search for specific sequences of nucleotides. The DNA sequence may be aligned with other DNA sequences to identify homologous sequences and locate the specific mutations that make them distinct. These techniques, especially multiple sequence alignment, are used in studying phylogenetic relationships and protein function. Data sets representing entire genomes' worth of DNA sequences, such as those produced by the Human Genome Project, are difficult to use without the annotations that identify the locations of genes and regulatory elements on each chromosome. Regions of DNA sequence that have the characteristic patterns associated with protein- or RNA-coding genes can be identified by gene finding algorithms, which allow researchers to predict the presence of particular gene products and their possible functions in an organism even before they have been isolated experimentally. Entire genomes may also be compared, which can shed light on the evolutionary history of particular organism and permit the examination of complex evolutionary events.",
            "score": 226.36691284179688
        },
        {
            "docid": "7955_46",
            "document": "DNA . In many species, only a small fraction of the total sequence of the genome encodes protein. For example, only about 1.5% of the human genome consists of protein-coding exons, with over 50% of human DNA consisting of non-coding repetitive sequences. The reasons for the presence of so much noncoding DNA in eukaryotic genomes and the extraordinary differences in genome size, or \"C-value\", among species, represent a long-standing puzzle known as the \"C-value enigma\". However, some DNA sequences that do not code protein may still encode functional non-coding RNA molecules, which are involved in the regulation of gene expression. Some noncoding DNA sequences play structural roles in chromosomes. Telomeres and centromeres typically contain few genes but are important for the function and stability of chromosomes. An abundant form of noncoding DNA in humans are pseudogenes, which are copies of genes that have been disabled by mutation. These sequences are usually just molecular fossils, although they can occasionally serve as raw genetic material for the creation of new genes through the process of gene duplication and divergence.",
            "score": 223.61231994628906
        },
        {
            "docid": "26412304_12",
            "document": "1000 Plant Genomes Project . Since only the transcriptome is being sequenced, the project will not reveal information about gene regulatory sequence, non-coding RNAs, DNA repetitive elements, or other genomic features that are not part of the coding sequence. Based on the few whole plant genomes collected so far, these non-coding regions will in fact make up the majority of the genome, and the non-coding DNA may actually be the primary driver of trait differences seen between species.",
            "score": 223.0637664794922
        },
        {
            "docid": "966654_7",
            "document": "DNA-binding protein . These DNA targets can occur throughout an organism's genome. Thus, changes in the activity of one type of transcription factor can affect thousands of genes. Thus, these proteins are often the targets of the signal transduction processes that control responses to environmental changes or cellular differentiation and development. The specificity of these transcription factors' interactions with DNA come from the proteins making multiple contacts to the edges of the DNA bases, allowing them to \"read\" the DNA sequence. Most of these base-interactions are made in the major groove, where the bases are most accessible. Mathematical descriptions of protein-DNA binding taking into account sequence-specificity, and competitive and cooperative binding of proteins of different types are usually performed with the help of the lattice models. Computational methods to identify the DNA binding sequence specificity have been proposed to make a good use of the abundant sequence data in the post-genomic era.",
            "score": 219.74807739257812
        },
        {
            "docid": "42966477_14",
            "document": "Nessa Carey . Carey's second book, \"Junk DNA: A Journey Through the Dark Matter of the Genome\", examines developments in the study of junk DNA, or noncoding DNA. DNA that doesn't code for proteins has been dismissed as nonfunctional until recently. She explains the \"most fundamental reason for the shift in emphasis is the sheer volume of junk DNA that our cells contain. One of the biggest shocks when the human genome sequence was completed in 2001 was the discovery that over 98 per cent of the DNA in a human is junk. It doesn't code for any proteins.\" Carey describes how this Junk DNA maintains the integrity of our chromosomes; regulates the ways the protein-coding genes are expressed; influences how we age and generally introduces incredible degrees of subtlety and flexibility into how we use the relatively small numbers of genes that code for proteins\u00a0... [and] contributes to all sorts of situations, from the correct control of gene expression in female cells to the regulation of pathways that drive cancer. From Ernest Hemingway's mutant cat to exoneration of the innocent through DNA fingerprinting, junk DNA impacts on an astonishing range of biological phenomena.",
            "score": 218.15664672851562
        },
        {
            "docid": "18398577_15",
            "document": "Somatic evolution in cancer . System instability is a major contributing factor for genetic heterogeneity. For the majority of cancers, genome instability is reflected in a large frequency of mutations in the whole genome DNA sequence (not just the protein coding regions that are only 1.5% of the genome). In whole genome sequencing of different types of cancers, large numbers of mutations were found in two breast cancers (about 20,000 point mutations), 25 melanomas (9,000 to 333,000 point mutations) and a lung cancer (50,000 point mutations and 54,000 small additions and deletions). Genome instability is also referred to as an enabling characteristic for achieving endpoints of cancer evolution. Many of the somatic evolutionary studies have traditionally been focused on clonal expansion, as recurrent types of changes can be traced to illustrate the evolutionary path based on available methods. Recent studies from both direct DNA sequencing and karyotype analysis illustrate the importance of the high level of heterogeneity in somatic evolution. For the formation of solid tumors, there is an involvement of multiple cycles of clonal and non-clonal expansion. Even at the typical clonal expansion phase, there are significant levels of heterogeneity within the cell population, however, most are under-detected when mixed populations of cells are used for molecular analysis. In solid tumors, a majority of gene mutations are not recurrent types, and neither are the karyotypes. These analyses offer an explanation for the findings that there are no common mutations shared by most cancers.",
            "score": 217.97340393066406
        },
        {
            "docid": "35746225_15",
            "document": "Cancer epigenetics . In mammals, microRNAs (miRNAs) regulate about 60% of the transcriptional activity of protein-encoding genes. Some miRNAs also undergo methylation-associated silencing in cancer cells. Let-7 and miR15/16 play important roles in down-regulating RAS and BCL2 oncogenes, and their silencing occurs in cancer cells. Decreased expression of miR-125b1, a miRNA that functions as a tumor suppressor, was observed in prostate, ovarian, breast and glial cell cancers. In vitro experiments have shown that miR-125b1 targets two genes, HER2/neu and ESR1, that are linked to breast cancer. DNA methylation, specifically hypermethylation, is one of the main ways that the miR-125b1 is epigenetically silenced. In patients with breast cancer, hypermethylation of CpG islands located proximal to the transcription start site was observed. Loss of CTCF binding and an increase in repressive histone marks, H3K9me3 and H3K27me3, correlates with DNA methylation and miR-125b1 silencing. Mechanistically, CTCF may function as a boundary element to stop the spread of DNA methylation. Results from experiments conducted by Soto-Reyes et al. indicate a negative effect of methylation on the function and expression of miR-125b1. Therefore, they concluded that DNA methylation has a part in silencing the gene. Furthermore, some miRNA's are epigenetically silenced early on in breast cancer, and therefore these miRNA's could potentially be useful as tumor markers. The epigenetic silencing of miRNA genes by aberrant DNA methylation is a frequent event in cancer cells; almost one third of miRNA promoters active in normal mammary cells were found hypermethylated in breast cancer cells - that is a several fold greater proportion than is usually observed for protein coding genes.  DNA damage appears to be the primary underlying cause of cancer. If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage can increase mutational errors during DNA replication due to error-prone translesion synthesis. Excess DNA damage can also increase epigenetic alterations due to errors during DNA repair. Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms).",
            "score": 216.4436798095703
        },
        {
            "docid": "70425_38",
            "document": "Inflammation . Genome-wide analyses of human cancer tissues reveal that a single typical cancer cell may possess roughly 100 mutations in coding regions, 10-20 of which are \u201cdriver mutations\u201d that contribute to cancer development. However, chronic inflammation also causes epigenetic changes such as DNA methylations, that are often more common than mutations. Typically, several hundreds to thousands of genes are methylated in a cancer cell (see DNA methylation in cancer). Sites of oxidative damage in chromatin can recruit complexes that contain DNA methyltransferases (DNMTs), a histone deacetylase (SIRT1), and a histone methyltransferase (EZH2), and thus induce DNA methylation. DNA methylation of a CpG island in a promoter region may cause silencing of its downstream gene (see CpG site and regulation of transcription in cancer). DNA repair genes, in particular, are frequently inactivated by methylation in various cancers (see hypermethylation of DNA repair genes in cancer). A 2018 report evaluated the relative importance of mutations and epigenetic alterations in progression to two different types of cancer. This report showed that epigenetic alterations were much more important than mutations in generating gastric cancers (associated with inflammation). However, mutations and epigenetic alterations were of roughly equal importance in generating esophageal squamous cell cancers (associated with tobacco chemicals and acetaldehyde, a product of alcohol metabolism).",
            "score": 215.26904296875
        },
        {
            "docid": "26062564_26",
            "document": "Cancer genome sequencing . A major goal of cancer genome sequencing is to identify driver mutations: genetic changes which increase the mutation rate in the cell, leading to more rapid tumor evolution and metastasis. It is difficult to determine driver mutations from DNA sequence alone; but drivers tend to be the most commonly shared mutations amongst tumors, cluster around known oncogenes, and are tend to be non-silent. Passenger mutations, which are not important in the progression of the disease, are randomly distributed throughout the genome. It has been estimated that the average tumor carries c.a. 80 somatic mutations, fewer than 15 of which are expected to be drivers.",
            "score": 212.51980590820312
        },
        {
            "docid": "235550_13",
            "document": "Sequence analysis . Gene prediction or gene finding refers to the process of identifying the regions of genomic DNA that encode genes. This includes protein-coding genes as well as RNA genes, but may also include the prediction of other functional elements such as regulatory regions. Gene finding is one of the first and most important steps in understanding the genome of a species once it has been sequenced. In general, the prediction of bacterial genes is significantly simpler and more accurate than the prediction of genes in eukaryotic species that usually have complex intron/exon patterns. Identifying genes in long sequences remains a problem, especially when the number of genes is unknown. Hidden markov models can be part of the solution. Machine learning has played a significant role in predicting the sequence of transcription factors. Traditional sequencing analysis focused on the statistical parameters of the nucleotide sequence itself (The most common programs used are listed in Table 4.1). Another method is to identify homologous sequences based on other known gene sequences (Tools see Table 4.3). The two methods described here are focused on the sequence. However, the shape feature of these molecules such as DNA and protein have also been studied and proposed to have an equivalent, if not higher, influence on the behaviors of these molecules.",
            "score": 211.75570678710938
        },
        {
            "docid": "31599765_6",
            "document": "Simon Boulton . DNA is highly reactive and susceptible to damage from things we are exposed to in everyday life. Fortunately, DNA has evolved processes in which it has the ability to repair itself. If the damages are not repaired and it continues to grow, mutagenic changes occur causing ageing and cancer. Boulton is responsible for identifying these new DNA repair genes, understanding how these genes work in DNA, and determining how the defects in these processes contribute to human diseases. To fulfil these tasks, Boulton studies the DNA damage repair inside a specific worm called C. elegans, then extends these findings to human cells. Through this process, he has found \"remarkable similarities between the genes and proteins used to repair DNA damage in the worm and in humans...By studying this fundamental process of DNA damage repair, the researchers have contributed to our understanding of how faults in the system can lead to cancer.\" Boulton's research has resulted in several major breakthroughs that are viewed as highly promising with regard to the potential development of new cancer treatments.",
            "score": 211.10678100585938
        },
        {
            "docid": "8310787_37",
            "document": "Survivin . As observed through the literature, survivin is found to be over-expressed across many tumour types. Scientists are not sure of the mechanism that causes this abnormal over-expression of survivin; however, p53 is downregulated in almost all cancers, so it is tempting to suggest that survivin over-expression is due to p53 inactivity. Wagner \"et al.\" investigated the possible molecular mechanism involved with the over expression of survivin in acute myeloid leukemia (AML). In their experiments, they did both an epigenetic and a genetic analysis of the survivin gene promoter region in AML patients and compared the observations to what was seen in peripheral blood mononuclear cells (PBMCs) that have been shown to express no survivin. Assuming that the molecular mechanism of survivin re-expression in cancerous cells is at the transcriptional level, the authors decided to look at particular parts of the promoter region of survivin in order to see what happens in cancer cells that does not happen in normal cells that causes such a high level of survivin to be expressed. With regards to an epigenetic mechanism of survivin gene regulation, the authors measured the methylation status of the survivin promoter, since it is accepted that methylation of genes plays an important role in carcinogenesis by silencing of certain genes or vice versa. The authors used methylation specific polymerase chain reaction with bisulfite sequencing methods to measure the promoter methylation status in AML and PBMCs and found unmethylated survivin promoters in both groups. This result shows that DNA methylation status is not an important regulator of survivin re-expression during leukemogenesis. However, De Carvalho \"et al.\" performed a DNA methylation screening and identified that DNA methylation of IRAK3 plays a key role in survivin up-regulation in different types of Cancer, suggesting that epigenetic mechanisms plays an indirect role on abnormal over-expression of survivin. With regard to genetic analysis of the survivin promoter region, the isolated DNA of AML and PBMCs were treated with bisulfite, and the survivin promoter region sequence was amplified out with PCR and sequenced to look for any particular genetic changes in the DNA sequence between the two groups. Three single-nucleotide polymorphisms (SNPs) were identified and were all present both in AML patients and in healthy donors. This result suggests that the occurrence of these SNPs in the promoter region of the survivin gene also appears to be of no importance to survivin expression. However, it has not been ruled out yet that there may be other possible epigenetic mechanisms that may be responsible for a high level of survivin expression observed in cancer cells and not in normal cells. For example, the acetylation profile of the survivin promoter region can also be looked at. Different cancer and tissue types may have slight or significant differences in the way survivin expression is regulated in the cell, and, thus, the methylation status or genetic differences in the survivin promoter may be observed to be different in different tissues. Thus, further experiments assessing the epigenetic and genetic profile of different tumour types must be investigated.",
            "score": 210.94631958007812
        },
        {
            "docid": "57021789_9",
            "document": "Propionispira raffinosivorans . The genome of \"P. raffinosivorans\" DSM 20765 is the only strain of this species to be completely sequenced using Illumina HiSeq 2000 technology by the DOE's Joint Genome Institute on April 24th, 2013, allowing quantification of genome length at 4.13 Megabp. The Whole Genome Shotgun Sequencing method aided in sequence identification, developed by Staden et al. 1979, in which DNA was fragmented randomly and amplified to produce overlap between short sequences of DNA, which were then used in primary assembly. Primary genome assembly, known as scaffold level assembly, provided a rough map of DNA sequence orientation and location, but is still incomplete with a total gap of 2,843 bps in the DNA that have yet to be correctly inserted and oriented for chromosomal reconstruction. Assembly of the genome was attempted using the windows program Velvet 1.1.04, created by Zerbino et al. 2008, in conjunction with the program ALLPATHS v. R37654, providing an accurate reconstruction of 99.9994% of the draft genome. The genome G-C content was identified to be 38.1% and the assembled genome was shown to code for 3,772 proteins, with the 30S ribosomal protein S2 being used as a non-redundant protein reference for taxonomic placement.",
            "score": 210.77780151367188
        },
        {
            "docid": "35048427_8",
            "document": "LIG3 . Unlike the LIG1 and LIG4 genes, inherited mutations in the LIG3 gene have not been identified in the human population. DNA ligase III-alpha has, however, been indirectly implicated in cancer and neurodegenerative diseases. In cancer, DNA ligase III-alpha is frequently overexpressed and this serves as a biomarker to identify cells that are more dependent upon the alternative NHEJ pathway for the repair of DNA double strand breaks. Although the increased activity of the alternative NHEJ pathway causes genomic instability that drives disease progression, it also constitutes a novel target for the development of cancer cell-specific therapeutic strategies. Several genes encoding proteins that interact directly with DNA ligase III-alpha or indirectly via interactions with XRCC1 have been identified as being mutated in inherited neurodegenerative diseases. Thus, it appears that DNA transactions involving DNA ligase III-alpha play an important role in maintaining the viability of neuronal cells.",
            "score": 209.573486328125
        },
        {
            "docid": "12388_17",
            "document": "Genome . Most bacteria have little or no repetitive DNA, hence their typical protein coding capacity is in the range of 85-90%. However, some symbiotic bacteria (e.g. \"Serratia symbiotica\") have reduced genomes and a high fraction of pseudogenes: only ~40% of their DNA encodes proteins. Simple eukaryotes such as \"C. elegans\" and fruit fly, possess more non-repetitive DNA than repetitive DNA. Higher eukaryotes tend to have more repetitive DNA than non-repetitive ones. In some plants and amphibians, the proportion of repetitive DNA is more than 80%. Similarly, only 2% of the human genome codes for proteins.  Noncoding sequences include introns, sequences for non-coding RNAs, regulatory regions, and repetitive DNA. Noncoding sequences make up 98% of the human genome. There are two categories of repetitive DNA in the genome: tandem repeats and interspersed repeats.",
            "score": 208.66387939453125
        },
        {
            "docid": "4087965_15",
            "document": "Genetic analysis . This research has been able to identify the concepts of genetic mutations, fusion genes and changes in DNA copy numbers, and advances are made in the field every day. Much of these applications have led to new types of sciences that use the foundations of genetic analysis. Reverse genetics uses the methods to determine what is missing in a genetic code or what can be added to change that code. Genetic linkage studies analyze the spatial arrangements of genes and chromosomes. There have also been studies to determine the legal and social and moral effects of the increase of genetic analysis. Genetic analysis may be done to identify genetic/inherited disorders and also to make a differential diagnosis in certain somatic diseases such as cancer. Genetic analyses of cancer include detection of mutations, fusion genes, and DNA copy number changes.",
            "score": 206.7628631591797
        },
        {
            "docid": "44284_21",
            "document": "Non-coding DNA . Though the fruitfulness of the term \"junk DNA\" has been questioned on the grounds that it provokes a strong \"a priori\" assumption of total non-functionality and though some have recommended using more neutral terminology such as \"noncoding DNA\" instead; \"junk DNA\" remains a label for the portions of a genome sequence for which no discernible function has been identified and that through comparative genomics analysis appear under no functional constraint suggesting that the sequence itself has provided no adaptive advantage. Since the late 70s it has become apparent that the majority of non-coding DNA in large genomes finds its origin in the selfish amplification of transposable elements, of which W. Ford Doolittle and Carmen Sapienza in 1980 wrote in the journal \"Nature\": \"When a given DNA, or class of DNAs, of unproven phenotypic function can be shown to have evolved a strategy (such as transposition) which ensures its genomic survival, then no other explanation for its existence is necessary.\" The amount of junk DNA can be expected to depend on the rate of amplification of these elements and the rate at which non-functional DNA is lost. In the same issue of \"Nature\", Leslie Orgel and Francis Crick wrote that junk DNA has \"little specificity and conveys little or no selective advantage to the organism\". The term occurs mainly in popular science and in a colloquial way in scientific publications, and it has been suggested that its connotations may have delayed interest in the biological functions of noncoding DNA.",
            "score": 205.2692413330078
        },
        {
            "docid": "30142141_11",
            "document": "Adaptive evolution in the human genome . Estimates of the amount of adaptive evolution in non-coding DNA are generally very low, although fewer studies have been done on non-coding DNA. As with the coding DNA however, the methods currently used are relatively weak. Ponting and Lunter (2006) speculate that underestimates may be even more severe in non-coding DNA, because non-coding DNA may undergo periods of functionality (and adaptive evolution), followed by periods of neutrality. If this is true, current methods for detecting adaptive evolution are inadequate to account for such patterns. Additionally, even if low estimates of the amount of adaptive evolution are correct, this can still equate to a large amount of adaptively evolving non-coding DNA, since non-coding DNA makes up approximately 98% of the DNA in the human genome. For example, Ponting and Lunter (2006) detect a modest 0.03% of non-coding DNA showing evidence of adaptive evolution, but this still equates to approximately 1 Mb of adaptively evolving DNA. Where there is evidence of adaptive evolution (which implies functionality) in non-coding DNA, these regions are generally thought to be involved in the regulation of protein coding sequences. As with humans, fewer studies have searched for adaptive evolution in non-coding regions of other organisms. However, where research has been done on Drosophila, there appears to be large amounts of adaptively evolving non-coding DNA. Andolfatto (2005) estimated that adaptive evolution has occurred in 60% of untranslated mature portions of mRNAs, and in 20% of intronic and intergenic regions. If this is true, this would imply that much non-coding DNA could be of more functional importance than coding DNA, dramatically altering the consensus view. However, this would still leave unanswered what function all this non-coding DNA performs, as the regulatory activity observed thus far is in just a tiny proportion of the total amount of non-coding DNA. Ultimately, significantly more evidence needs to be gathered to substantiate this viewpoint.",
            "score": 205.26510620117188
        },
        {
            "docid": "7737653_21",
            "document": "Oncogenomics . As pointed out by Gao et al., the stability and integrity of the human genome are maintained by the DNA-damage response (DDR) system. Un-repaired DNA damage is a major cause of mutations that drive carcinogenesis. If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage can increase mutational errors during DNA replication due to error-prone translesion synthesis. Excess DNA damage can also increase epigenetic alterations due to errors during DNA repair. Such mutations and epigenetic alterations can give rise to cancer. DDR genes are often repressed in human cancer by epigenetic mechanisms. Such repression may involve DNA methylation of promoter regions or repression of DDR genes by a microRNA. Epigenetic repression of DDR genes occurs more frequently than gene mutation in many types of cancer (see Cancer epigenetics). Thus, epigenetic repression often plays a more important role than mutation in reducing expression of DDR genes. This reduced expression of DDR genes is likely an important driver of carcinogenesis.",
            "score": 203.7078399658203
        },
        {
            "docid": "46335535_11",
            "document": "Hox genes in amphibians and reptiles . As previously mentioned, Hox genes encode transcription factors that regulate embryonic and post-embryonic developmental processes. The expression of Hox genes is regulated in part by the tight, spatial arrangement of conserved coding and non-coding DNA regions. The potential for evolutionary alterations in Hox cluster composition is viewed to be small among vertebrates. On the other hand, recent studies of a small number of non-mammalian taxa propose greater dissimilarity than initially considered. Next, generation sequencing of considerable genomic fragments greater than 100 kilobases from the eastern newt (\"Notophthalmus viridescens\") was analyzed. Subsequently, it was found that the composition of Hox cluster genes were conserved relative to orthologous regions from other vertebrates. Furthermore, it was found that the length of introns and intergenic regions varied. In particular, the distance between HoxD13 and HoxD11 is longer in newt than orthologous regions from vertebrate species with expanded Hox clusters and is predicted to exceed the length of the entire HoxD clusters (HoxD13\u2013HoxD4) of humans, mice, and frogs. Many recurring DNA sequences were recognized for newt Hox clusters, counting an enrichment of DNA transposon-like sequences similar to non-coding genomic fragments. Researchers found the results to suggest that Hox cluster expansion and transposon accumulation are common features of non-mammalian tetrapod vertebrates. After the loss of a limb, cells draw together to form a clump known as a blastema. This superficially appears undifferentiated, but cells that originated in the skin later develop into new skin, muscle cells into new muscle and cartilage cells into new cartilage. It is only the cells from just beneath the surface of the skin that are pluripotent and able to develop into any type of cell. Salamander Hox genomic regions show elements of conservation and variety in comparison to other vertebrate species. Whereas the structure and organization of Hox coding genes is conserved, newt Hox clusters show variation in the lengths of introns and intergenic regions, and the HoxD13\u201311 region exceeds the lengths of orthologous segments even among vertebrate species with expanded Hox clusters. Researchers have suggested that the HoxD13\u201311 expansion predated a basal salamander genome size amplification that occurred approximately 191 million years ago, because it preserved in all three extant amphibian groups. Supplementary verification supports the proposal that Hox clusters are acquiescent to structural evolution and variation is present in the lengths of introns and intergenic regions, relatively high numbers of repetitive sequences, and non-random accumulations of DNA transposons in newts and lizards. Researchers found that the non-random accretion of DNA-like transposons could possibly change developmental encoding by generating sequence motifs for transcriptional control.",
            "score": 203.11376953125
        },
        {
            "docid": "18214141_55",
            "document": "Western honey bee . The European honey bee is the third insect, after the fruit fly and the mosquito, to have its genome mapped. According to scientists who analyzed its genetic code, the honey bee originated in Africa and spread to Europe in two ancient migrations. Scientists have found that genes related to smell outnumber those for taste, and the European honey bee has fewer genes regulating immunity than the fruit fly and the mosquito. The genome sequence also revealed that several groups of genes, particularly those related to circadian rhythm, resembled those of vertebrates more than other insects. Another significant finding from the honey bee genome study was that honey bee was the first insect to be discovered with a functional DNA methylation system because functional key enzymes (DNA methyl-transferase 1 and 3) were identified in the genome. DNA methylation is one of the important mechanisms in epigenetics to study gene expression and regulation without changing the DNA sequence, but modifications on the DNA. DNA methylation later was identified to play an important role in gene regulation and gene alternative splicing. The genome is unusual in having few transposable elements, although they were present in the evolutionary past (inactive remains have been found) and evolved more slowly than those in fly species.",
            "score": 202.86520385742188
        },
        {
            "docid": "4110763_20",
            "document": "Extrachromosomal DNA . Sometimes called EEs, extrachromosomal elements, have been associated with genomic instability in eukaryotes. Small polydispersed DNAs (spcDNAs) are commonly found in conjunction with genome instability. SpcDNAs are derived from repetitive sequences such as satellite DNA, retrovirus-like DNA elements, and transposable elements in the genome. They are thought to be the products of gene rearrangements. Double minute chromosomes (DMs) are also extrachromosomal elements that are associated with genome instability. DMs are commonly seen in cancer cells. DMs are thought to be produced through breakages in chromosomes or overreplication of DNA in an organism. Studies show that in cases of cancer and other genomic instability, higher levels of EEs can be observed.",
            "score": 202.81324768066406
        },
        {
            "docid": "4250553_22",
            "document": "Gene . Prokaryotes (bacteria and archaea) typically store their genomes on a single large, circular chromosome. Similarly, some eukaryotic organelles contain a remnant circular chromosome with a small number of genes. Prokaryotes sometimes supplement their chromosome with additional small circles of DNA called plasmids, which usually encode only a few genes and are transferable between individuals. For example, the genes for antibiotic resistance are usually encoded on bacterial plasmids and can be passed between individual cells, even those of different species, via horizontal gene transfer. Whereas the chromosomes of prokaryotes are relatively gene-dense, those of eukaryotes often contain regions of DNA that serve no obvious function. Simple single-celled eukaryotes have relatively small amounts of such DNA, whereas the genomes of complex multicellular organisms, including humans, contain an absolute majority of DNA without an identified function. This DNA has often been referred to as \"junk DNA\". However, more recent analyses suggest that, although protein-coding DNA makes up barely 2% of the human genome, about 80% of the bases in the genome may be expressed, so the term \"junk DNA\" may be a misnomer.",
            "score": 202.6748046875
        },
        {
            "docid": "42683705_3",
            "document": "Epigenetics and melanoma . In the last few years, chemical alterations in the genome have become more evident, and these alterations can be critical in the development of malignancy. This alteration process is referred to as epigenetics (Patino et al. 2008). Epigenetics is the term used to refer to stable changes in DNA that affect gene expression but do not involve changes in the underlying nucleotide sequence of the organism (Patino et al. 2008). The mechanisms by which epigenetics occur involve hypo- and hypermethylation of DNA, histone modifications by acetylation, methylation, and phosphorylation, and posttranslational modifications which include RNA silencing. These modifications can cause different expression patterns to occur, which can result in alterations to cells. Some of these alterations could result in the formation of cancerous cells or various other dangerous changes in cell function, among many other outcomes when paired together. Cancerous cells are not formed from just one change.",
            "score": 202.53431701660156
        },
        {
            "docid": "10487520_9",
            "document": "Ehrlichia . The evolutionary changes in the outer membrane proteins have led to the emergence of new strains which can infect a larger variety of hosts. Heartwater, caused by \"Ehrlichia\" ruminantium, is a prevalent tick-borne disease of livestock in Africa and the Caribbean but also threatens the American mainland. Three strains have arisen from this species due to evolutionary change in their genomes. When sequencing their genomes, there were many active genomic modifications such as high substitution rates, truncated genes, and the presence of pseudogenes and tandem repeats. When analyzing substitution rates between the three strains in 888 orthologous coding DNA sequences, it was observed that there were only 3 coding DNA sequences that were biased towards non-synonymous substitutions that affect phenotype. In contrast, 181 coding DNA sequences were biased towards synonymous substitutions which do not affect phenotype. This indicates that there was a selection pressure to maintain protein function, and this selection acted against the non-synonymous mutations.",
            "score": 202.0453338623047
        }
    ]
}